文献リスト

1）Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361: 1058-66

2）Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366: 1079-89

3）Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368: 2059-74

4）Gruber TA, Larson Gedman A, Zhang J, et al. An inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012; 22: 683-97

5）de Rooij JD, Hollink IH, Arentsen-Peters ST, et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia. (in press)

6）Masetti R, Pigazzi M, Togni M, et al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013; 121: 3469-72

7）Yoshida K, Toki T, Okuno Y, et al. Landscape of gene mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013; 45: 1293-9

8）Nikolaev SI, Santoni F, Vannier A, et al. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood. 2013; 122: 554-61

9）Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29: 551-65

10）Hayashi Y. The molecular genetics of recurring chromosome abnormalities in acute myeloid leukemia. Semin Hematol. 2000; 37: 368-80

11）Nagao T, Lampkin BC, Hug G. A neonate with Downʼs syndrome and transient abnormal myelopoiesis: serial blood and bone marrow studies. Blood. 1970; 36: 443-7

12）新保敏和，長尾　大，木村清次，他．白血病様血液像を呈したDown症候群（6症例）の臨床経過ならびに病理解剖所見の検討−特にTransient Abnormal Myelopoiesis (TAM)の概念について−．臨床血液．1977; 18: 99-109

13）Hayashi Y, Eguchi M, Sugita K, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Downʼs syndrome. Blood. 1998; 72: 15-23

14）Zipursky A. Transient leukaemia−a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol. 2003; 120: 930-8

15）Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005; 5: 11-20

16）Miyauchi J, Ito Y, Kawano T, et al. Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Downʼs syndrome: a report of four autopsy cases and proposal of a hypothesis. Blood. 1992; 80: 1521-7

17）Al-Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2002; 24: 9-13

18）Massey GV, Zipursky A, Chang MN, et al. Childrenʼs Oncology Group (COG). A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Childrenʼs Oncology Group (COG) study POG-9481. Blood. 2006; 107: 4606-13

19）Brodeur GM, Dahl GV, Williams DL, et al. Transient leukemoid reaction and trisomy 21 mosaicism in a phenotypically normal newborn. Blood. 1980; 55: 691-3

20）Klusmann JH, Creutzig U, Zimmermann M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008; 111: 2991-8

21）Gamis AS, Woods WG, Alonzo TA, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Childrenʼs Cancer Group Study 2891. J Clin Oncol. 2003; 21: 3415-22

22）Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005; 19: 1355-60

23）Muramatsu H, Kato K, Watanabe N, et al. Risk factors for early death in neonates with Down syndrome and transient leukaemia. Br J Haematol. 2008; 142: 610-5

24）林　泰秀．ダウン症候群に発症したtransient abnormal myelopoiesis(TAM)への対応．周産期医学．2010; 40: 937-41

25）Kitoh T, Taki T, Hayashi Y, et al. Transient abnormal myelopoiesis in a Down syndrome newborn followed by acute myeloid leukemia: identification of the same chromosomal abnormality in both stages. Cancer Genet Cytogenet. 2009; 188: 99-102

26）Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008; 111; 1575-83

27）Dastugue N, Lafage-Pochitaloff M, Pagès MP, et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématolo-gique(GFCH). Blood. 2002; 100: 618-26

28）Hama A, Yagasaki H, Takahashi Y, et al. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome. Br J Haematol. 2008; 140: 552-61

29）Ma Z, Morris SW, Valentine V, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1; 22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet. 2001; 28: 220-1

30）Mercher T, Coniat MB, Monni R, et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci U S A. 2001; 98: 5776-9

31）Bernstein J, Dastugue N, Haas OA, et al. Nineteen cases of the t(1;22)(p13;q13) acute megaka-ryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia. 2000; 14: 216-8

32）Carroll A, Civin C, Schneider N, et al. The t(1; 22)(p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood. 1991; 78: 748-52

33）Hara Y, Shiba N, Ohki K, et al. Comprehensive fusion gene analysis of pediatric non-Down syndrome acute megakaryoblasitc leukemia. ASH#2646. 2013

34）Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood. 2000; 96: 2405-11

35）Reinhardt D, Diekamp S, Langebrake C, et al. Acute megakaryoblastic leukemia in children and adolescents, excluding Downʼs syndrome: improved outcome with intensified induction treatment. Leukemia. 2005; 19: 1495-6

36）Athale UH, Razzouk BI, Raimondi SC, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institutionʼs experience. Blood. 2001; 97: 3727-32

37）Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009; 114: 2489-96

38）Kong XT, Ida K, Ichikawa H, et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood. 1997; 90: 1192-9

39）Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002; 100: 1532-42

40）Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-38

41）Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42: 722-6

42）Abe K, Kajii T, Niikawa N, et al. Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative syndrome. Hum Gent. 1989; 82: 561-6

43）Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002; 32: 148-52

44）Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003; 102: 2960-8

45）Shimada A, Xu G, Toki T, et al. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Blood. 2004; 103: 366

46）Kanezaki R, Toki T, Terui K, et al. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood. 2010; 116: 4631-8

47）Toki T, Kanezaki R, Kobayashi E, et al. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome. Blood. 2013; 121: 3181-4

48）Nasmyth K, Haering CH. Cohesin: its roles and mechanisms. Annu Rev Genet. 2009; 43: 525-58

49）Park MJ, Shimada A, Asada H, et al. JAK2 mutation in a boy with polycythemia vera, but not in other pediatric hematologic disorders. Leukemia. 2006; 20: 1453-4

50）Malinge S, Ragu C, Della-Valle V, et al. Activating mutations in human acute megakaryoblastic leukemia. Blood. 2008; 112: 4220-6

51）Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006; 10: 65-75

52）De Vita S, Mulligan C, McElwaine S, et al. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome. Br J Haematol. 2007; 137: 337-41

53）Norton A, Fisher C, Liu H, et al. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood. 2007; 110: 1077-9

54）Blink M, Buitenkamp TD, van den Heuvel-Eibrink MM, et al. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011; 25: 1365-8

55）Kiyoi H, Yamaji S, Kojima S, et al. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia. 2007; 21: 574-6

56）Hama A, Yagasaki H, Takahashi Y, et al. JAK mutations in Down syndrome-associated transient myeloproliferative disorder and acute megakaryocytic leukemia. Blood. 2008; 111: 2493-4

57）Hama A, Muramatsu H, Makishima H, et al. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia. Br J Haematol. 2012; 156: 316-25

58）Malkin D, Brown EJ, Zipursky A. The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. Cancer Genet Cytogenet. 2000; 116: 1-5

59）Thiollier C, Lopez CK, Gerby B, et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med. 2012; 209: 2017-31

60）Klusmann JH, Reinhardt D, Hasle H, et al. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Downʼs syndrome. Leukemia. 2007; 21: 1584-7

61）Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150: 264-78

62）Wen Q, Goldenson B, Silver SJ, et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell. 2012; 150: 575-89

63）Sano H, Shimada A, Tabuchi K, et al. WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2013; 98: 437-45

64）Hussein K, Bock O, Theophile K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia. 2009; 23: 852-5

65）Oki K, Takita J, Hiwatari M, et al. IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies. Leukemia. 2011; 25: 382-4

66）Taketani T, Taki T, Takita J, et al. Mutation of the AML1/RUNX1 gene in a transient myeloproliferative disorder patient with Down syndrome. Leukemia. 2002; 16: 1866-7

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp